Launch LNZ100 commercially in the United States
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 6 Nov 2024
- Due
- 31 Dec 2025
- Delivered
- October 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“advance LNZ100 towards approval in the United States and a commercial launch as early as the fourth quarter of 2025”
What we found
Evidence strength A What the grades mean
LNZ100, branded VIZZ, was FDA-approved in July 2025 and commercially launched in the U.S. in 2025 (August per the 10-K, first sale October), before the Q4 2025 deadline.
-
A LENZ Therapeutics, Inc. - Form 10-K - FY2025
“The Company commercially launched VIZZ in the U.S. in August 2025, with direct-to-eye care professional sales and marketing activities initiated immediately upon approval.” ✓ confirmed on the page
-
A LENZ Therapeutics, Inc. - Form 10-K - FY2025
“On July 31, 2025, the FDA approved VIZZ, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia in adults.” ✓ confirmed on the page
-
B LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates
“First commercial product sale of VIZZ in October 2025” ✓ confirmed on the page
Checked 10 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Commercial launch
- Indicative materiality
- Medium rules
- Action
- Launch
- Deliverable
- LNZ100 commercial launch
- Where
- United States
- In the company’s control
- Medium
- Specificity
- Medium
- Conditional
- Yes: subject to regulatory approval
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Gemini (Google), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you LENZ Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2024-LENZ-003366 · Corrections policy